GSK-J4 targeting KDM6A is an effective therapeutic strategy against craniosynostosis (35), lymphoblastic and myeloid leukemias (37, 38), and breast, ovarian and prostate cancers (39–41). Here, KDM6A is linked to craniosynostosis.